investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Mechanisms of action of a TCR-like antibody to WT1
David A Scheinberg
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
David A Scheinberg
Memorial Sloan Kettering Cancer Center
New York, United States
Related projects
Catherine Ju-Ying Wu
(PQD1) Impact of Cytotoxic and Targeted Therapy on Clonal Evolution of CLL
Leukaemia
Pathology
Hematology and hematologic malignancies
Peter Aplan
Collaborative Pathways that Lead to Leukemia
Leukaemia
Pathology
Hematology and hematologic malignancies
Wenwei Hu
The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer
Leukaemia
Effie W Petersdorf
Clinical Significance of MHC Haplotypes in HCT
Leukaemia
Hamid Band
Tyrosine Kinase Regulation Via Protein Degradation
Leukaemia
Pathology
Hematology and hematologic malignancies
Amy Paguirigan
Connecting Single Cell Heterogeneity to Clinical Descriptors of Clonal Evolution in Acute Myeloid Leukemia
Leukaemia
Dean W Felsher
Mechanisms by which Oncogene Inactivation Elicits Tumor Cell Death
Leukaemia
Omar Abdel-Wahab
Role of ASXL1 mutations in myeloid malignancies
Leukaemia
Yves Pommier
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
Leukaemia